The company achieved revenue of €118.84 million in 2024, representing 17.55% year-over-year growth. PharmaSGP maintains a focused portfolio of branded OTC products with strong market positioning in the German pharmacy channel, leveraging a lean operational structure with approximately 91 employees to deliver margins above 31% EBITDA.
Cyborg Score Rationale
PharmaSGP demonstrates solid fundamentals with consistent revenue growth (17.55% in 2024), healthy EBITDA margins (31.32%), and profitable operations. The company has a stable market position in the OTC pharmaceutical segment with established branded products, though limited scale and geographic concentration present growth constraints.
Top Insights
Strong revenue growth momentum: 17.55% YoY increase in 2024 to €118.84M, with earnings up 19.14%
Exceptional operational efficiency with 31.32% EBITDA margins on a lean 91-employee base
Diversified OTC portfolio spanning sleep disorders, pain management, sexual wellness, cardiovascular health, and dermatology
Geographic expansion opportunity with current presence in Austria, Italy, Belgium, Spain, France alongside core German market
Named Competitors
Aspirin and ibuprofen portfolio — Global OTC pain relief and wellness products
Regional OTC pharmaceutical products — European generic and OTC pharmaceutical manufacturer
Herbal and botanical remedies — Natural medicine and homeopathic products
Recent Developments
(2024) Revenue reached €118.84M, up 17.55% YoY with earnings of €19.54M (+19.14%)
(2025) Analyst consensus 1-year price target of €39.50, implying significant upside from current levels
Open the full interactive PharmaSGP Holding SE report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.